simplyStocks
Haemonetics Corporation
HAE · NYSEHealth Care
The economic chain
Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
$3.3B
P/E ratio
24×
Div yield
0%
EPS (TTM)
$2.40
Profit margin
9%
Rev. growth
+4%
Revenue
$1.36B
Free cash flow
$160M
In plain English
Haemonetics is a blood-and-plasma medtech: it builds the automated machines and single-use kits that draw, separate and manage blood. Its razor-and-blades model sells devices plus a recurring stream of disposables to three customer worlds — commercial plasma collectors (CSL, Grifols, Takeda), blood centers, and hospitals — where it has been buying its way into higher-growth interventional cardiology (~$1.36B revenue, FY2025).
In simple terms
What Haemonetics Corporation really sells
Haemonetics is a blood-and-plasma medtech: it builds the automated machines and single-use kits that draw, separate and manage blood. Its razor-and-blades model sells devices plus a recurring stream of disposables to three customer worlds — commercial plasma collectors (CSL, Grifols, Takeda), blood centers, and hospitals — where it has been buying its way into higher-growth interventional cardiology (~$1.36B revenue, FY2025).
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.
Risk read
SteadierMore speculative
Why this rating?